Gene Editing Technology Platform
Pioneering PD-1 Knockout & Universal CAR-T
Early global leader in clinical application for solid tumor treatment.
Advanced Solid Tumor Applications
Proven efficacy in lung, esophageal, and breast cancers.
Precise Target Design
Bioinformatics-driven selection for optimal editing outcomes
High-Efficiency Gene Delivery
Lipid transfection, electroporation, and viral vector systems.
Comprehensive Off-Target Analysis
Whole-genome sequencing and targeted deep sequencing for safety assurance.
Integrated Multi-Platform Synergy
Combines with cell manufacturing, analysis, and therapy development platforms for enhanced outcomes.
Cutting-Edge Applications in Solid Tumor Therapy
We have applied PD-1 knockout CAR-T technology to treat non-small cell lung cancer, esophageal cancer, breast cancer, and other solid tumors, achieving significant clinical responses and improving patient outcomes. By targeting and deleting immunogenicity-related genes such as MHC, universal CAR-T development has paved the way for scalable, off-the-shelf therapies.
Technical Advantages
Our CRISPR/Cas9-based gene editing platform excels in precise target design, high-efficiency gene delivery (lipid transfection, electroporation, and viral vectors), and optimization of editing parameters to maximize editing rates. Comprehensive off-target analysis using whole-genome sequencing and bioinformatics ensures safety and reliability. We also create gene-edited immune cell models to study disease mechanisms and support drug discovery.
Flow cytometry analysis of CAR positivity
Flow cytometry for PD-1 gene knockout detection
Sanger sequencing for PD-1 knockout validation
Integrated Innovation
The platform seamlessly integrates with our cell culture, analytical, sequencing, and immunotherapy development capabilities, enabling enhanced functional analysis and therapeutic performance. This synergy accelerates the translation of gene editing research into next-generation immune cell therapies.
